Ashleigh Murphy-Beiner
Assistant Psychologist at Imperial College London Centre for Psychedelic Research
Data updated
Research Footprint
Ashleigh Murphy-Beiner appears in 10 tracked papers (2020–2024), most studied alongside Psilocybin, LSD and Ayahuasca, across Anxiety Disorders, Depressive Disorders and Major Depressive Disorder (MDD).
Most-cited paper: Trial of Psilocybin versus Escitalopram for Depression (1334 citations).
Frequent co-authors: Robin Murphy, David Nutt and Robin Carhart-Harris.
Publication Landscape
How the 10 papers Blossom tracks for Ashleigh Murphy-Beiner line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Ashleigh Murphy-Beiner's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 10 of 10 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Ashleigh Murphy-Beiner publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Ashleigh Murphy-Beiner publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
A. Murphy-Beiner is a clinical researcher active in contemporary psychedelic science whose published and in-preparation work centres on the psychological sequelae of psychedelic use and on strategies for coping and integration. Their research portfolio, drawn from mixed-methods, qualitative and survey-based studies, includes investigation of ayahuasca’s ‘afterglow’ and its associations with mindfulness and cognitive flexibility; a mixed-methods study and qualitative analyses documenting extended difficulties following psychedelic use; and interview work exploring ontological shock and existential distress after powerful psychedelic experiences.
Murphy-Beiner has also contributed to research comparing therapeutic outcomes of psilocybin-assisted therapy against conventional antidepressant treatment (psilocybin therapy v. escitalopram), with interest in personality change and broader mental-health outcomes. Across these projects they emphasise rigorous qualitative methodology, participant-centred descriptions of challenging experiences, and practical supports and coping strategies for people experiencing protracted difficulties after psychedelic sessions. (Note: the full given name was not available in the supplied sources.)
Key Impact
Recognised for empirical and qualitative work on the aftereffects of psychedelic experiences, emphasising extended difficulties, coping and integration as well as psychological outcomes after ceremonial and clinical use.
Collaboration Network
19 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Ashleigh Murphy-Beiner's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Ashleigh Murphy-Beiner is associated with.
Imperial College London
academicThe Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →Clerkenwell Health
UK psychedelic and CNS trial infrastructure provider with specialist trial sites, sponsor-facing psychiatric research support, recruitment pathways, and therapist-related trial expertise.
View stakeholder →